Aimin Zang

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 211 citations

Versus Gefitinib, Medicine, Pathology +8

Circular RNA: Biogenesis, Degradation, Functions and Potential Roles in Mediating Resistance to Anticarcinogens

Xiuchao Geng, Youchao Jia, Yuhao Zhang et al. · Epigenomics · 2019 · 115 citations · Full text

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Zefei Jiang, Quchang Ouyang, Tao Sun et al. · Nature Medicine · 2024 · 90 citations

Breast Oncology, Medicine, Pharmacology +6

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · Journal of Thoracic Oncology · 2022 · 71 citations

Neuro-oncology, Versus Gefitinib, Furlong Study +6

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

Chun Han, Sisi Ye, Chunhong Hu et al. · Frontiers in Oncology · 2021 · 63 citations · Full text